SBC Medical Group Expands To The US Via Strategic Investment In OrangeTwist
MWN-AI** Summary
SBC Medical Group Holdings Inc. (NASDAQ: SBC), a Japanese company known for its chain of aesthetic medical clinics, has officially entered the U.S. market through a strategic investment in OrangeTwist, a nationwide medspa chain specializing in non-invasive aesthetic treatments. The announcement, made on January 15, 2026, marks SBC's intention for a comprehensive expansion in the U.S. and beyond. Currently managing over six million patient visits annually across 258 clinics worldwide, SBC aims to leverage its global network and OrangeTwist’s established operational framework to accelerate growth in the highly lucrative medical aesthetics sector.
OrangeTwist operates 24 locations across six states, offering a variety of injectable, energy-based, and regenerative treatments. SBC's CEO, Yoshiyuki Aikawa, highlighted the synergy between the two organizations and expressed enthusiasm about combining their strengths to enhance service delivery in both the U.S. and Asia. OrangeTwist’s CEO, Robert Settembro, echoed these sentiments, emphasizing that the partnership will enable the delivery of high-quality aesthetic experiences while expanding into high-growth markets.
The U.S. medical aesthetics market is projected to grow from $34 billion to $48 billion by 2030, driven by increasing demand for non-surgical treatments, fueled further by an aging population. SBC plans to implement a multi-year roadmap, with initial investments and partnerships aimed at establishing a competitive foothold in the U.S. and Southeast Asia. This expansion strategy also includes management support for a new dermatological clinic in Bangkok, Thailand, reflecting SBC's commitment to explore new opportunities in the growing aesthetic landscape.
MWN-AI** Analysis
SBC Medical Group Holdings Inc. (NASDAQ: SBC) is embarking on a strategic expansion into the U.S. aesthetic medical market through its investment in OrangeTwist, marking a significant milestone in its growth trajectory. This partnership positions SBC to capitalize on a booming industry projected to grow from $34 billion to $48 billion by 2030, driven by increasing demand for non-surgical treatments, particularly among the aging population.
Investors should view this development as a positive signal for SBC’s future prospects. The collaboration with OrangeTwist, already a recognized leader in non-invasive aesthetic treatments, allows SBC to leverage advanced management systems and operational efficiencies, enhancing their scalability across U.S. regions. As both firms aim to introduce new beauty products and services, this synergy could lead to increased revenue opportunities.
Phase One of SBC’s expansion roadmap emphasizes strategic investments and partnerships, which is evident with their existing e-consulting agreement in Southeast Asia. As SBC builds its footprint in the U.S. and beyond, it’s prudent for investors to monitor further developments, especially with the planned acquisitions and joint ventures in subsequent phases.
While the immediate outlook appears promising, potential investors should conduct due diligence. Key factors to watch include the competitive landscape in the U.S. aesthetic market, SBC's execution of its expansion strategy, and how effectively it can integrate OrangeTwist’s operations. Given these dynamics, SBC may present a compelling opportunity for investors seeking exposure in the growing medical aesthetics sector. However, caution is advised due to the inherent risks of market entry and the need for sustained growth amid competition.
Overall, this strategic investment serves as a crucial stepping stone for SBC Medical Group, making it a stock to watch as they potentially reshape their market presence over the coming years.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
By Meg Flippin, Benzinga
DETROIT, MICHIGAN - January 15, 2026 (NEWMEDIAWIRE) - SBC Medical Group Holdings Inc. (NASDAQ: SBC), the Japanese owner and operator of a chain of aesthetic medical clinics and a provider of consulting and management services, made its foray into the U.S. official with the completion of a strategic investment in OrangeTwist, a U.S.-based medspa chain.
SBC Medical Group already has a network of 258 affiliated clinics worldwide and manages more than six million patient visits annually. This investment marks the beginning of its “full-scale” strategic expansion in the U.S. Through the partnership with OrangeTwist, the two companies will pursue joint operations, leveraging their synergies in the U.S. and Asia.
Pursuing Growth In Medical Aesthetics
OrangeTwist specializes in non-invasive aesthetic treatments and currently operates 24 locations across six U.S. states. The company offers clients a menu of injectable, energy-based and regenerative treatments. SBC said OrangeTwist’s advanced management system - which integrates procurement, clinical workflows and real-time KPI tracking - provides operational consistency with SBC and supports scalable growth.
“OrangeTwist has solidified its leadership in the U.S. market by consistently delivering exceptional quality and outstanding client experiences in non-invasive aesthetic medicine,” said Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings. “We look forward to combining their strengths with our expertise and global network to accelerate growth across Asia and beyond.” In addition to selling each other's services and products in the U.S. and Japan, the companies plan to collaborate on new beauty products and services.
"We are thrilled to deepen our strategic partnership with SBC Medical Group Holdings while expanding our presence in high-growth markets," said Robert Settembro, CEO of OrangeTwist. "This next chapter allows us to bring exceptional aesthetic experiences to more communities while leveraging SBC’s global expertise. We remain focused on high-quality care, best-in-class providers, and innovative services that continue to differentiate OrangeTwist in a rapidly growing aesthetic landscape."
Phase One Underway
The deal is the first step in SBC’s multiyear roadmap to establish a leading position in the medical aesthetics and wellness market largely by expanding internationally, namely in the U.S. and Southeast Asia. SBC Medical is already in a strong position in Japan.
The U.S. is an important market for SBC Medical for good reasons. The medical aesthetics industry is forecast to grow from $34 billion today to $48 billion by 2030, reports SBC. Some of the drivers of demand for non-surgical treatments include injectables, fillers, laser treatments and body contouring that offer little risk and downtime. The aging population in the U.S. is also driving demand for aesthetic treatments.
During 2026, SBC Medical plans to make more strategic investments and ink partnerships like the one with OrangeTwist to expand in the U.S. and in Southeast Asia. It already did so last year in Southeast Asia through its e-consulting agreement with BLEZ ASIA Co. Ltd. BLEZ ASIA operates more than 20 pharmacies and clinics in Thailand, and according to SBC, is widely trusted by both Japanese expatriates and local patients.
As part of the deal, SBC will provide management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC said the partnership is a key component of the company’s broader Asia expansion strategy and represents a big step toward entering the growing Thai market. Those two deals are the type of arrangements the company is pursuing during the first phase of its expansion.
Phase 2 of SBC’s plan, which is slated for 2027 and 2028, will be dedicated to making select acquisitions and joint ventures that accelerate growth and boost its competitive position. Phase 3, which commences in 2029 and on, is when SBC expects to be in leadership positions in the U.S., Southeast Asia and other key markets.
SBC Medical is in expansion mode, and its investment in OrangeTwist is the first step in that plan to make its mark in the U.S. and beyond. The deal gives it a foothold in the U.S. and is only the beginning of this multiyear strategy. To learn more about SBC Medical Group and what it has planned, click here.
Featured image credit: OrangeTwist.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
This content was originally published on Benzinga. Read further disclosures here.
BenzingaFAQ**
How does SBC Medical Group Holdings Incorporated SBC plan to leverage its partnership with OrangeTwist to enhance its operational efficiency and client experience in the expanding U.S. aesthetic market?
With SBC Medical Group Holdings Incorporated SBC’s expansion strategy, what specific metrics will be used to gauge the success of its collaboration with OrangeTwist within the first year?
Given that the medical aesthetics industry is projected to grow significantly, how does SBC Medical Group Holdings Incorporated SBC intend to differentiate its services from existing competitors in the U.S. market?
What future investments does SBC Medical Group Holdings Incorporated SBC foresee making in both the U.S. and Southeast Asia to fulfill its multiyear roadmap for growth in the medical aesthetics sector?
**MWN-AI FAQ is based on asking OpenAI questions about SBC Medical Group Holdings Incorporated (NASDAQ: SBC).
NASDAQ: SBC
SBC Trading
-0.52% G/L:
$3.83 Last:
5,622 Volume:
$3.79 Open:
